Short-term Observation on the Clinical Application Effect of Astra Tech Implant EV Short Implants for Maxillary Sinus Elevation

NCT07271134 · tracked via the Priya Life Science China tracker

Sponsor

Linhu Wang

Phase

Not applicable

Started

2025-12-10

Last updated

2025-12-16

Condition(s) studied

Missing Teeth

Investigational drug(s) / intervention(s)

short implants (L=6.3mm)short implants (L=8mm)conventional implants (L=9mm)

short implants (L=6.3mm): Short-term clinical outcome of Astra OsseoSpeed EV short implants (L=6.3mm) for transcrestal sinus floor elevation

short implants (L=8mm): Short-term clinical outcome of Astra OsseoSpeed EV short implants (L=8mm) for transcrestal sinus floor elevation

conventional implants (L=9mm): conventional implants (L=9mm) in the posterior maxillary region for dental restoration

Study summary

Short-term comparison of clinical application effects of Astra OsseoSpeed EV short implants and conventional implants for maxillary sinus elevation

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Patients aged over 18 years old with at least one area of the posterior dental arch having insufficient alveolar bone height (3-6 mm) * Patients are in good health and have no major systemic diseases such as diabetes or cardiovascular diseases, and no maxillary sinus lesions * They are willing to undergo implant restoration treatment and can complete at least 3-year follow-up. Exclusion Criteria: * horizontal bone deficiency alveolar ridges,bone defects caused by tumor resection * excessive tobacco use (more than 10 cigarettes per day) * severe liver and kidney diseases * history of radiotherapy and chemotherapy in the head and neck region * uncontrolled diabetes * active periodontal disease * oral mucosal diseases in the treatment area or poor oral hygiene, * PI \> 70%

Primary outcome measure(s)

Various complications — From having a tooth implant to one year after wearing the dentures
the rate of Implant survival, swelling, pain, etc.

Trial sites (1)

Facility	City	Region	Status
No. 26, Shengli Street, Jiang'an District, Wuhan City, Hubei Province, China	Wuhan	Hubei

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07271134 on ClinicalTrials.gov ↗ ← All trials in China